Skip to main content

Table 2 Multivariate survival analyses for distant metastasis-free survival and overall survival

From: Association of neutrophil-to-lymphocyte ratio, radiotherapy fractionation/technique, and risk of development of distant metastasis among patients with locally advanced rectal cancer

  DMFS OS
p value HR 95% CI p value HR 95% CI
Age (≥ 60 vs. < 60 years) 0.017 0.99 0.98–1.00 < 0.001 1.02 1.03–1.06
Sex (male vs. female) 0.606 1.07 0.84–1.36 0.896 0.90 0.60–1.33
Clinical T stage (icT3/4 vs. icT1/2) 0.529 1.20 0.68–2.11 0.479 1.28 0.53–3.08
Clinical N stage (icN1/2 vs. icN0) 0.961 0.93 0.70–1.391 0.160 0.73 0.46–1.14
RT modality (tomotherapy vs. 3D-CRT) 0.459 1.12 0.83–1.53 0.354 0.73 0.38–1.41
Year of diagnosis (> 2013 vs. ≤ 2013) 0.852 0.97 0.72–1.31 < 0.001 0.51 0.51–0.52
PostRT NLR ≥ 4.0 vs. < 4.0 0.004 1.42 1.12–1.80 < 0.001 2.22 1.54–3.20
ypT (ypT3/4 vs. ypT1/2) < 0.001 1.96 1.46–2.62 0.001 2.13 1.34–3.37
ypN (ypN1/2 vs. ypN0) < 0.001 2.43 1.80–3.27 0.167 1.37 0.88–2.15
Adjuvant chemotherapy (no vs. yes) 0.552 0.91 0.67–1.24 0.700 0.92 0.60–1.41
RT fractionation (LCRT vs. SCRT) 0.417 0.44 0.06–3.17 0.962 < 0.01 0.00–4.34E+181
  1. DMFS distant metastasis-free survival, OS overall survival, HR hazard ratio, CI confidence interval, NLR neutrophil-to-lymphocyte ratio, LCRT long-course RT, SCRT short-course RT